Sun Pharma net profit up 2 per cent in Q2

Copyright thehindubusinessline

Sun Pharmaceutical Industries clocked a net profit of ₹3,118 crore, for the second quarter ended September 30, up 2.6 per cent from the same period last year. Its sales grew 8.6 per cent to ₹14,405 crore Kirti Ganorkar, Sun Pharma Managing Director, said, “India, Emerging Markets and Rest of World led our growth for the period. US sales of innovative medicines have surpassed generics for the first time during the quarter. We remain focused on broadening our portfolio while strengthening in-house talent pool and execution capability.” . Sun’s global Innovative Medicines sales (specialty business) stood at $333 million, up 16.4 per cent and accounting for 20.2 per cent of sales. The company’s sale of formulations (finished form of medicine) in India was ₹4,734 crore, a 11 per cent growth, and the segment accounted for 32.9 per cent of the total consolidated sales for the quarter. The company said it had launched nine new products during the quarter and 15 products in the year to date. Formulation sales The company’s formulation sales in the US were $496 million, a 4.1 per cent decline. The decline in generics business was offset by growth in Innovative Medicines, the company said, as US sales accounted for approximately 30.1 per cent of total consolidated sales. Its Emerging Markets formulations sales were $325 million for the quarter under review, up 10.9 per cent and accounting for 19.7 per cent of total consolidated sales. Formulation sales in Rest of World (RoW) markets were $234 million, up 17.7 per cent and accounting for 14.2 per cent of total consolidated sales for the quarter. In the said quarter, external sales of Active Pharmaceutical Ingredients were ₹429 crore, down 19.5 per cent. “Our API portfolio supports our formulation business and API customers across geographies,” the company said. On the research front, Sun’s innovative R&D pipeline included six novel entities in clinical stage. Its spending on research and development was ₹782 crore, or 7 5.4 per cent of sales, it said. Published on November 5, 2025